- Potential to receive FDA approval of beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukoodystrophy in 2022.
- FDA approvals of beti-cel and eli-cel would give bluebird bio the ability to receive Priority Review Vouchers which it could sell for upwards of over $100 million each.
- A 3rd FDA approved gene therapy by the name of lovo-cel for SCD is possible as a BLA filing for this program is expected in Q1 of 2023.
- The global sickle-cell disease treatment market is expected to reach 7.71 billion by 2027.
For further details see:
bluebird bio: Beaten Down Biotech With Possible Long-Term Potential